Mapping the next steps: how men with advanced prostate cancer are treated after standard therapies fail

This study looks at real-world data from over 1,000 men with metastatic castration-resistant prostate cancer (mCRPC) who have already received several standard treatments, including hormone therapy, chemotherapy, and a targeted radiation drug called Lu-177 PSMA-617. Researchers will analyze treatment patterns, patient characteristics, and outcomes to understand what happens next in routine clinical practice. The goal is to gather insights that may help guide future treatment decisions for this advanced cancer.